Kendra D. Tutsch
Impact in
- Oncology top 5%
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
Papers in
- Oncology 15
- Cancer Treatment and Pharmacology 10
- Colorectal Cancer Treatments and Studies 4
-
- Polyamine Metabolism and Applications 4
- Cancer therapeutics and mechanisms 2
- Co-authors
- Dona Alberti (24 shared papers)George Wilding (22 shared papers)Rhoda Arzoomanian (18 shared papers)Rebecca Marnocha (10 shared papers)Howard H. Bailey (10 shared papers)Marcia Pomplun (8 shared papers)Chris Feierabend (10 shared papers)Kim Binger (6 shared papers)
- Journals
- Cancer Chemotherapy and Pharmacology (7 papers)Investigational New Drugs (5 papers)Clinical Cancer Research (2 papers)International Journal of Radiation Oncology*Biology*Physics (2 papers)Journal of Clinical Oncology (2 papers)
- Partner nations
- United StatesSpainGermany
In The Last Decade
Kendra D. Tutsch
40 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 101
- Oncology 443
- Cancer Research 178
- Pathology and Forensic Medicine 206
- Molecular Biology 742
- Biochemistry 78
Countries citing papers authored by Kendra D. Tutsch
This map shows the geographic impact of Kendra D. Tutsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kendra D. Tutsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kendra D. Tutsch more than expected).
Fields of papers citing papers by Kendra D. Tutsch
This network shows the impact of papers produced by Kendra D. Tutsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kendra D. Tutsch. The network helps show where Kendra D. Tutsch may publish in the future.
Co-authors
The 25 scholars most cited alongside Kendra D. Tutsch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 192 | |
| 2 | 2004 | 139 | |
| 3 | Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. | 2000 | 138 |
| 4 | 2002 | 103 | |
| 5 | Phase I clinical trial of perillyl alcohol administered daily. | 1998 | 100 |
| 6 | Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. | 2000 | 91 |
| 7 | 1986 | 81 | |
| 8 | Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. | 1983 | 61 |
| 9 | 2005 | 59 | |
| 10 | 2007 | 58 | |
| 11 | 2003 | 52 | |
| 12 | A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. | 1998 | 48 |
| 13 | Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. | 1998 | 43 |
| 14 | Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. | 1988 | 40 |
| 15 | Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. | 1990 | 34 |
| 16 | 2013 | 32 | |
| 17 | Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. | 2001 | 27 |
| 18 | 1999 | 26 | |
| 19 | 2003 | 23 | |
| 20 | Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. | 1985 | 20 |
About Kendra D. Tutsch
Kendra D. Tutsch is a scholar working on Oncology, Molecular Biology, Pathology and Forensic Medicine, Pharmacology and Biochemistry, having authored 40 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (4 papers), Chemotherapy-induced organ toxicity mitigation (4 papers), Polyamine Metabolism and Applications (4 papers), Amino Acid Enzymes and Metabolism (3 papers), Pharmacogenetics and Drug Metabolism (3 papers), Acute Lymphoblastic Leukemia research (2 papers) and Cancer therapeutics and mechanisms (2 papers). The work is most often cited by research in Oncology (443 citations), Cancer Research (178 citations), Pathology and Forensic Medicine (206 citations), Molecular Biology (742 citations) and Biochemistry (78 citations). Kendra D. Tutsch has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Dona Alberti, George Wilding, Rhoda Arzoomanian, Rebecca Marnocha, Howard H. Bailey, Marcia Pomplun, Chris Feierabend, Kim Binger, James P. Thomas and Robert H. Earhart. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Investigational New Drugs, Clinical Cancer Research, International Journal of Radiation Oncology*Biology*Physics and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.